Randomized trial shows CD19-targeting CAR T cells induce remission in antisynthetase syndrome, suggesting a new treatment option.
CD19-targeting CAR T cells directed against B cells and plasmablasts deeply reset B-cell immunity. Together with mycophenolate mofetil, CD19-targeting CAR T cells may break pathologic B-cell, as well as T-cell responses, inducing remission in refractory antisynthetase syndrome.
No takes yet. Share an insight, caveat, or question.
Pecher et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: